Antoinette R Tan1,2, Nancy Chan3, Brian F Kiesel4, Mark N Stein3,5, Rebecca A Moss3,6, Jyoti Malhotra3, Joseph Aisner3, Mansi Shah3, Murugesan Gounder3, Hongxia Lin3, Michael P Kane3, Yong Lin3, Jiuping Ji7, Alice Chen8, Jan H Beumer4, Janice M Mehnert3,9. 1. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. Antoinette.Tan@atriumhealth.org. 2. Atrium Health, Levine Cancer Institute, 1021 Morehead Medical Drive, Charlotte, NC, 28204, USA. Antoinette.Tan@atriumhealth.org. 3. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 4. University of Pittsburgh, Pittsburgh, PA, USA. 5. Columbia University Medical Center, New York, NY, USA. 6. Bristol-Myers Squibb, Lawrenceville, NJ, USA. 7. Frederick National Lab for Cancer Research, Bethesda, MD, USA. 8. Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA. 9. New York University Langone Health's Perlmutter Cancer Center, New York, NY, USA.
Abstract
PURPOSE: Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C. METHODS: Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1-4 plus C 450 to 750 mg/m2 Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 in 21-day cycles. In Group 3, patients received AC Day 1 plus V Days 1-7, and in Group 4, AC Day 1 plus V Days 1-14 was given in 21-day cycles to evaluate effects on γH2AX foci. RESULTS: Eighty patients were enrolled. MTD was not reached for V and C. MTD for V and AC was V 100 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 every 21 days. V PK appears to be dose-dependent and has no effect on the PK of C. Overall, neutropenia and anemia were the most common adverse events. Objective response in V and AC treated groups was 22% (11/49). Overall clinical benefit rate was 31% (25/80). PAR decreased in PBMCs. Percentage of γH2AX-positive CTCs increased after treatment with V and AC. CONCLUSION: V and AC can be safely combined. Activity was observed in patients with metastatic breast cancer.
PURPOSE: Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C. METHODS: Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1-4 plus C 450 to 750 mg/m2 Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 in 21-day cycles. In Group 3, patients received AC Day 1 plus V Days 1-7, and in Group 4, AC Day 1 plus V Days 1-14 was given in 21-day cycles to evaluate effects on γH2AX foci. RESULTS: Eighty patients were enrolled. MTD was not reached for V and C. MTD for V and AC was V 100 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 every 21 days. V PK appears to be dose-dependent and has no effect on the PK of C. Overall, neutropenia and anemia were the most common adverse events. Objective response in V and AC treated groups was 22% (11/49). Overall clinical benefit rate was 31% (25/80). PAR decreased in PBMCs. Percentage of γH2AX-positive CTCs increased after treatment with V and AC. CONCLUSION: V and AC can be safely combined. Activity was observed in patients with metastatic breast cancer.
Authors: Shivaani Kummar; Jiuping Ji; Robert Morgan; Heinz-Josef Lenz; Shannon L Puhalla; Chandra P Belani; David R Gandara; Deborah Allen; Brian Kiesel; Jan H Beumer; Edward M Newman; Larry Rubinstein; Alice Chen; Yiping Zhang; Lihua Wang; Robert J Kinders; Ralph E Parchment; Joseph E Tomaszewski; James H Doroshow Journal: Clin Cancer Res Date: 2012-02-03 Impact factor: 12.531
Authors: Urban Emmenegger; Yuval Shaked; Shan Man; Guido Bocci; Ivan Spasojevic; Giulio Francia; Andrew Kouri; Robert Coke; William Cruz-Munoz; Susan M Ludeman; O Michael Colvin; Robert S Kerbel Journal: Mol Cancer Ther Date: 2007-08-01 Impact factor: 6.261
Authors: Jesus Anampa; Alice Chen; John Wright; Margi Patel; Christine Pellegrino; Karen Fehn; Joseph A Sparano; Eleni Andreopoulou Journal: Clin Breast Cancer Date: 2017-09-01 Impact factor: 3.225
Authors: Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost Journal: Clin Cancer Res Date: 2007-05-01 Impact factor: 12.531
Authors: Robert A Parise; Mohammad Shawaqfeh; Merrill J Egorin; Jan H Beumer Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2008-07-31 Impact factor: 3.205
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Shivaani Kummar; James L Wade; Amit M Oza; Daniel Sullivan; Alice P Chen; David R Gandara; Jiuping Ji; Robert J Kinders; Lihua Wang; Deborah Allen; Geraldine O'Sullivan Coyne; Seth M Steinberg; James H Doroshow Journal: Invest New Drugs Date: 2016-03-21 Impact factor: 3.850
Authors: Eve T Rodler; Brenda F Kurland; Melissa Griffin; Julie R Gralow; Peggy Porter; Rosa F Yeh; Vijayakrishna K Gadi; Jamie Guenthoer; Jan H Beumer; Larissa Korde; Sandra Strychor; Brian F Kiesel; Hannah M Linden; John A Thompson; Elizabeth Swisher; Xiaoyu Chai; Stacie Shepherd; Vincent Giranda; Jennifer M Specht Journal: Clin Cancer Res Date: 2016-01-22 Impact factor: 12.531
Authors: Lihua H Wang; Thomas D Pfister; Ralph E Parchment; Shivaani Kummar; Larry Rubinstein; Yvonne A Evrard; Martin E Gutierrez; Anthony J Murgo; Joseph E Tomaszewski; James H Doroshow; Robert J Kinders Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: Julia Manzo; Shannon Puhalla; Shalu Pahuja; Fei Ding; Yan Lin; Leonard Appleman; Hussein Tawbi; Ronald Stoller; James J Lee; Brenda Diergaarde; Brian F Kiesel; Jing Yu; Antoinette R Tan; Chandra P Belani; Helen Chew; Agustin A Garcia; Robert J Morgan; Andrea E Wahner Hendrickson; Daniel W Visscher; Rachel M Hurley; Scott H Kaufmann; Elizabeth M Swisher; Steffi Oesterreich; Tiffany Katz; Jiuping Ji; Yiping Zhang; Ralph E Parchment; Alice Chen; Wenrui Duan; Vincent Giranda; Stacie P Shepherd; S Percy Ivy; Edward Chu; Jan H Beumer Journal: Cancer Chemother Pharmacol Date: 2022-04-18 Impact factor: 3.288